"Kevetrin Pharmacokinetics Kevetrin showed a bipha

"Kevetrin Pharmacokinetics Kevetrin showed a biphasic time vs. drug concentration curve with an elimination half-life of about 0.7 to 2.2 hours in mice and rats, respectively, and 1 hour in dogs and a dose dependent pattern in terms of the plasma concentration, C max, and exposure." The half-life in humans will likely approximate the half-life found in the animal studies. Half-life measures the time it takes for an administered drug to decrease its concentration in the body by 50%. This drug has short half-life - so there most likely won't be large accumulation in the body, even at mtd. There has not been evidence to support the idea that Kevetrin corrects p53 function in the long-term, only when it is active in the body. So far - it seems to be treatment specific - give it - get rid of the cancer - stop giving it. Once the MTD is established by having one patient out of 6 reach a point of dose limiting toxicity, the researchers will enroll 12 patients and administer the max tol dose to confirm if, indeed, they have reached the maximum. (maximum is when one patient out of six is made sick by the drug). Maximum tolerated dose is not the dose that will be administered long term - it is the established upper threshold of tolerability - and once it is known then work begins on comparing minimum efficacious dose threshold to MTD to find best and safest dose range.